Although pre-clinical studies have indicated that Dasatinib, an SRC inhibitor, shows promise for treating NSCLC subjects [8], clinical trials showed modest response when compared to established chemotherapeutic agents [9]. Here, SRC is linked to non-small cell lung carcinoma.